Abstract-Minocycline, a second-generation tetracycline, is well known for its antibiotic, anti-inflammatory, and antinociceptive effects. Modulation of synaptic transmission is one of the analgesic mechanisms of minocycline. Although it has been reported that minocycline may suppress excitatory glutamatergic synaptic transmission, it remains unclear whether it could affect inhibitory synaptic transmission, which also plays a key role in modulating pain signaling. To examine the effect of minocycline on synaptic transmission in rat spinal substantia gelatinosa (SG) neurons, we recorded spontaneous inhibitory postsynaptic currents (sIPSCs) using whole-cell patch-clamp recording at a holding potential of 0 mV. Bath application of minocycline significantly increased the frequency but not the amplitude of sIPSCs in a reversible and concentration-dependent manner with an EC 50 of 85. The enhancement of inhibitory synaptic transmission produced by minocycline was not affected by the glutamate receptor antagonists CNQX and D-APV or by the voltage-gated sodium channel blocker tetrodotoxin (TTX). Moreover, the potency of minocycline for facilitating sIPSC frequency was the same in both glycinergic and GABAergic sIPSCs without changing their decay phases. However, the facilitatory effect of minocycline on sIPSCs was eliminated in a Ca 2+ -free Krebs solution or by co-administration with calcium channel blockers. In summary, our data demonstrate that baseline inhibitory synaptic transmission in SG neurons is markedly enhanced by minocycline. This may function to decrease the excitability of SG neurons, thus leading to a modulation of nociceptive transmission. 
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INTRODUCTION
In addition to being well known as a broad-spectrum antibiotic, minocycline is also a microglial activation inhibitor that contributes to pain alleviation. The analgesic effect of minocycline was initially reported in a rat pain model of L5 spinal nerve transection, in which intraperitoneal administration of minocycline could potently attenuate mechanical allodynia and hyperalgesia (Raghavendra et al., 2003) . The antinociceptive role of minocycline has been examined in diverse pathological states, such as neuropathy (Ledeboer et al., 2005; Padi and Kulkarni, 2008; Guasti et al., 2009; Ma et al., 2010) , inflammation (Hua et al., 2005; Cho et al., 2006; Kannampalli et al., 2014) , cancer (Mao-Ying et al., 2012) , chemotherapy (Di Cesare Mannelli et al., 2014) and diabetes (Pabreja et al., 2011; Ali et al., 2014; Syngle et al., 2014) . In addition, minocycline not only improved the analgesic effect of morphine (Chen et al., 2010; Nazemi et al., 2012; Makuch et al., 2013; Zychowska et al., 2013) but also attenuated or delayed morphine tolerance (Mika et al., 2009; Zhang et al., 2015) . These studies suggest that minocycline might be a promising agent for the clinical treatment of pain when being used alone or when combined with opioids. The underlying mechanisms for antinociception of minocycline have been extensively studied. Currently, most of the studies are based on the effect of minocycline on the inhibition of microglial activation and subsequent inflammatory cytokine secretion (Garrido-Mesa et al., 2013) . However, several studies have suggested that minocycline might also regulate neuronal activity directly. For instance, minocycline inhibited Na + currents in dorsal root ganglion (DRG) cells (Kim et al., 2011) , suppressed Na + and Ca 2+ currents in hippocampal neurons (Gonzalez et al., 2007) , and reduced evoked synaptic currents (Cho et al., 2006) and hyperpolarization-activated cation currents (Liu et al., 2015) [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] unmyelinated C primary afferent fibers but also receives information from local dorsal horn interneurons and the endogenous descending inhibitory system (Melzack and Wall, 1965; Wall, 1980) . Spinal disinhibition, such as loss of GABAergic inhibition, is thought to be one of the essential mechanisms of neuropathic pain (Moore et al., 2002) . Consistent with this, intrathecal administration of GABA was shown to attenuate neuropathic pain (Eaton et al., 1999) . It has been reported that intrathecal administration of minocycline could inhibit chemokine CCL2-induced enhancement of glutamatergic excitatory postsynaptic currents (EPSCs) in SG neurons (Huang et al., 2014) . To date, little is known about the effect of minocycline on spontaneous inhibitory postsynaptic currents (sIPSCs).
In this study, we examined the effects and the underlying cellular mechanisms of minocycline on sIPSCs and miniature IPSCs (mIPSCs) in rat spinal SG neurons. We found that minocycline largely enhances the frequency, but not the amplitude, of inhibitory postsynaptic currents (IPSCs), suggesting that presynaptic mechanisms contribute to the effects of minocycline with the involvement of voltage-activated calcium channels.
EXPERIMENTAL PROCEDURES
All animal experimental protocols were approved by the Animal Ethics Committee of Nanchang University. We aimed to minimize the suffering of the animals and to reduce the number of rats studied.
Slice preparation
Parasagittal spinal cord slices were prepared as in previous studies (Lu et al., 2013; Liu et al., 2015) . Briefly, male Sprague-Dawley rats (3-5 weeks old) were deeply anesthetized with urethan (1.5 g/kg, i.p.) and were then transcardially perfused with ice-cold carbogenated (95% O 2 and 5% CO 2 ) dissection solution containing (in mM) 240 sucrose, 2.5 KCl, 3.5 MgCl 2 , 0.5 CaCl 2 , 1.25 NaH 2 -PO 4 , 0.4 ascorbic acid, 2 pyruvate, and 25 NaHCO 3 . The lumbosacral section was quickly removed and immersed in the dissection solution. After extraction, the animals were sacrificed by exsanguination while still under anesthesia. The pia-arachnoid membrane was removed after cutting all ventral and dorsal roots. The spinal section was then mounted on a vibratome (VT1000S; Leica) cutting stage. Parasagittal slices (300-lm-thick) were cut and placed in an incubator filled with normal carbogenated Krebs solution for at least 30 min at 32°C. The normal Krebs solution contained (in mM) 117 NaCl, 3.6 KCl, 2.5 CaCl 2 , 1.2 MgCl 2 , 1.2 NaH 2 PO 4 , 25 NaHCO 3 , 11 Dglucose, 0.4 ascorbic acid, and 2 pyruvate.
Patch-clamp recordings
Whole-cell voltage-clamp recordings in SG neurons were operated basically as described previously (Liu et al., 2008 (Liu et al., , 2015 . In brief, one spinal cord slice was moved to the recording chamber and continuously perfused with Krebs solution at room temperature at a perfusing rate of 2-4 ml/min. Recording electrodes were pulled from borosilicate glass (1.5 mm, 1.12 mm ID; World Precision Instruments) with a micropipette puller (P-97; Sutter Instrument). Typical resistance of the pipette was 3-5 MO when filled with intracellular solution. The holding potential (V H ) for recording GABAergic and/or glycinergic IPSCs was 0 mV (at which voltage glutamate-mediated EPSCs are negligible). The intracellular solution used to record IPSCs contained the following (in mM): 92 CsMeSO 4 , 43 CsCl, 10 phosphocreatine, 0.5 EGTA, 10 HEPES, 4 Mg-ATP, 0.3 Li-GTP, and 5 tetraethylammonium (TEA)-Cl (pH = 7.2, adjusted with CsOH, 300 mOsm). Potassium-channel blockers (Cs + and TEA) were used to steadily hold the membrane potentials at 0 mV. In some experiments, a nominally Ca 2+ -free Krebs solution was used with the following (in mM): 113.1 NaCl, 3.6 KCl, 5 MgCl 2 , 1.2 NaH 2 PO 4 , 11 glucose, and 25 NaHCO 3 (tonicity was adjusted by lowering the concentration of Na + ). Liquid junction potential was not corrected in this study. Signals were amplified with an EPC-10 amplifier and Patch master software (HEKA) and were stored on a computer for further analysis. Series resistances were generally 20-30 MO and were monitored during the recording. The data were not used if the series resistance change was >20%.
Application of drugs
All drugs were bath applied by gravity through three-way stopcocks. The time necessary for the solution to flow from the stopcocks to the slice was approximately 15 s. The drugs used were minocycline, 100 lM doxycycline (a second-generation tetracycline), 100 lM DL-fluorocitric acid barium salt (a selective astrocyte inhibitor), 10 lM CNQX (an AMPA/kainate receptor antagonist), 50 lM APV (an NMDA receptor antagonist), 0.5-1 lM tetrodotoxin (TTX, a voltage-gated sodium channel blocker), 10-40 lM bicuculline methiodide (a GABA A receptor antagonist), 1-2 lM strychnine (a glycine receptor antagonist), 100 lM NiCl 2 (a low voltageactivated calcium channel blocker), and 100 lM CdCl 2 (a high voltage-activated calcium channel blocker). Minocycline and doxycycline were freshly dissolved in Krebs solution at the final concentration before perfusion. A stock of fluorocitrate was prepared from DLfluorocitric acid barium salt as previously described (Wenker et al., 2010) . A stock of CNQX was first dissolved in dimethyl sulfoxide, and the other drugs were prepared in distilled water at 1000 times the concentrations to be used and stored at -20°C as in our previous study (Liu et al., 2015) . The drugs were diluted to the final concentration in Krebs solution just before use. Doxycycline, CNQX, APV, and TTX were obtained from Tocris Bioscience (Bristol, UK). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). The determination of the doses for minocycline was based on a previous study in which 100 lM minocycline markedly reduced the frequency and amplitude of spontaneous EPSCs (sEPSCs) in hippocampal neurons (Gonzalez et al., 2007) .
Statistical analysis
The frequencies and amplitudes of IPSCs were analyzed with Mini Analysis (version 6.0.3; Synaptosoft, Decatur, GA). Curve fittings were performed using GraphPad Prism 5.0 (GraphPad Software, USA). SPSS version 17.0 was used for all the statistical analysis, except where noted. The normal distribution of data was tested with the Shapiro-Wilk test. Homogeneity of variance was assessed by Levene test. The data were expressed as mean ± SEM; n indicates the number of neurons Comparisons between two dependent groups were conducted with Two-sample paired Student's t-tests. A one-way ANOVA followed by post hoc of Bonferroni correction was used for the comparisons of more than two groups. Kolmogorov-Smirnov test (KS test) was used for the comparison of cumulative probabilities of frequency and amplitude. The KS test was run online at http://www.physics.csbsju.edu/stats/KS-test.n.plot_form. html (Lowe and Bailey, 2015) . A difference was considered to be significant at P < 0.05.
RESULTS

Minocycline enhances inhibitory synaptic transmission in SG neurons
To investigate the effect of minocycline on inhibitory transmission, whole-cell voltage-clamp recordings from SG neurons were made under control conditions and after bath application of minocycline (100 lM). Minocycline treatment did not alter sIPSC amplitude, but gradually increased sIPSC frequency (Fig. 1A) . The frequency and amplitude of sIPSCs under the action of minocycline were 220 ± 10% (P < 0.05) and 105 ± 3% (P > 0.05) of the control (2.5 ± 0.3 Hz and 24.8 ± 2.0 pA), respectively (Fig. 1D ). This enhancement of sIPSC frequency by minocycline confirmed that it could increase the inhibitory neurotransmitter, i.e., GABA/glycine release from the presynaptic terminal. However, minocycline has been recognized as playing two mainly independent roles: it is a microglial inhibitor as well as a secondgeneration tetracycline. Since microglia is an upstream partner of astrocytes in response to stimuli (Pascual et al., 2012) , we next examined whether astrocyte activation will affect sIPSCs. Unlike minocycline, fluorocitrate itself did not affect the frequency and amplitude of sIPSCs (Fig. 1B, D) . When the slices were pretreated with fluorocitrate, we observed no differences in sIPSC frequency and amplitude with the bath application of minocycline (data not shown). The finding that fluorocitrate did not affect the minocycline responses suggests that the increase in sIPSC frequency by the latter drug might not be due to the role of astrocyte activation in the spinal dorsal horn. To further examine the possible molecular target, we applied a substitute second-generation tetracycline, doxycycline, to SG neurons. Similar to the effect of fluorocitrate on sIPSCs, doxycycline also did not affect sIPSCs (Fig. 1C) . Thus, the above results raise the possibility that minocycline may have some unknown action that affects neurons, and this possibility needs to be further investigated.
Minocycline enhances sIPSCs in a concentrationdependent manner
To examine whether the facilitatory effect of minocycline on sIPSCs is concentration dependent, we applied minocycline in a concentration range from 1 to 300 lM to spinal slices. The frequency of sIPSCs was not altered at 1 lM, but increased to 284 ± 27% of the control at 300 lM (n = 10, P < 0.05) ( Fig. 2A, B) . However, minocycline did not increase the amplitude of sIPSCs even at 300 lM (113 ± 6% of control, P > 0.05). This indicates that minocycline increases the probability of inhibitory neurotransmitter release from the presynaptic terminal into a synapse without a postsynaptic effect. In this study, concentrations of minocycline higher than 300 lM were not used because the drug could not be completely dissolved in Krebs solution at room temperature at a concentration of >300 lM. Taken together, our findings indicate that minocycline increases the frequency of sIPSCs in a concentration-dependent manner (EC 50 of 85 lM) without changing their amplitude, suggesting a presynaptic mechanism that contributes to the effect of minocycline (Fig. 2C ).
Minocycline increases both glycinergic and GABAergic sIPSC frequencies
In spinal SG neurons, both glycinergic and GABAergic sIPSCs were recorded as previously described (Yang et al., 2004; Liu et al., 2008) . To determine whether there was a difference in the effects of minocycline on glycinergic and GABAergic sIPSCs, we pretreated the slices with GABA A or glycine receptor antagonists to distinguish putative glycinergic and GABAergic sIPSCs (Fig. 3A, E) . As illustrated in Fig. 3C and G, minocycline increased the frequencies of glycinergic and GABAergic sIPSCs to 219 ± 7% (n = 8, P < 0.05) of the control (1.7 ± 0.3 Hz) and 214 ± 9% (n = 9, P < 0.05) of the control (1.6 ± 0.2 Hz), respectively. Cumulative distribution curves showed that minocycline shortened the interevent interval of glycinergic and GABAergic sIPSCs (P < 0.05; KS test) but did not affect the amplitude (P > 0.05; KS test) (Fig. 3D, H) . Furthermore, the decay phases of glycinergic and GABAergic sIPSCs were not altered by minocycline (Fig. 3B, F) . These data suggested that minocycline affects both glycinergic and GABAergic presynaptic terminals.
Inhibitory transmission enhancement produced by minocycline is independent of neuronal activity
To test the possibility that glutamatergic synaptic transmission affects the excitability of SG neurons and may be involved in the facilitation of minocycline on sIPSCs, we added the glutamate receptor blockers CNQX and APV into the bath solution before minocycline treatment. As shown in Fig. 4A , C, E, the enhancement effect of minocycline on sIPSCs was not abolished by glutamate receptor antagonists. The frequency increased to 217 ± 4% (n = 5, P < 0.05) of the control (2.0 ± 0.1 Hz). Similarly, minocycline had no effect on the amplitude of sIPSCs in the presence of CNQX and APV (Fig. 4C, E and Table 1) .
To further examine whether neuronal activity contributes to the increase in sIPSC frequency produced by minocycline, we next tested whether TTX affected the response of minocycline. As observed for the control conditions, minocycline significantly increased the frequency of mIPSCs (sIPSCs in the presence of TTX) to 236 ± 9% (n = 16, P < 0.05) of the control (2.2 ± 0.2 Hz) but not the amplitude (105 ± 3% of the control: 20.2 ± 1.2 pA) (Fig. 4D, E and Table 1 ). This increase was consistent with the results of cumulative distributions of the inter-event interval and the amplitude of sIPSCs in the absence and presence of minocycline. As illustrated in Fig. 4D , minocycline shifted the cumulative frequency distribution of mIPSC frequency to the left (P < 0.05; KS test) but did not change mIPSC amplitude (P > 0.05; KS test). Meanwhile, the facilitatory effect of minocycline on mIPSCs is not significantly different than its effect on sIPSCs (Fig. 4E) . These results clearly demonstrate that minocyclineinduced facilitation is not mediated by neuronal activity, but by direct action on the inhibitory presynaptic terminal.
Inhibitory transmission enhancement produced by minocycline is due to presynaptic Ca 2+ influx
To test whether presynaptic Ca 2+ influx was involved in the increase of IPSC frequency by minocycline, we first examined the effect of minocycline (100 lM) on sIPSCs in the presence of a nominally Ca 2+ -free Krebs solution. Consistent with previous findings (Yang et al., 2004; Liu et al., 2008) , we found that the lack of extracellular Ca 2+ itself reduced the frequency and amplitude of sIPSCs to 17 ± 2% (n = 11, P < 0.05) and 74 ± 3% (n = 11, P < 0.05) of the control (5.3 ± 0.4 Hz and 25.0 ± 1.3 pA), respectively (Fig. 5A) . Under the same conditions, minocycline did not affect the frequency and amplitude of sIPSCs, which were 100 ± 3% (n = 11, P > 0.05) and 102 ± 2% (n = 11, P > 0.05) of the control (0.9 ± 0.1 Hz and 18.2 ± 0.7 pA), respectively ( Fig. 5D and Table 1 ). This suggests that extracellular Ca 2+ is necessary for the minocycline-induced sIPSC frequency increase.
A variety of different types of voltage-gated calcium channels, such as N-type, R-type, and T-type, are expressed in the spinal dorsal horn, which is associated with pain signaling (Bourinet et al., 2014 ). Because it is not possible to test the effects of all of the calcium blockers in the present study, we selected a low voltage-activated (LVA) calcium channel blocker, NiCl 2 , and a high voltage-activated (HVA) calcium channel blocker, CdCl 2 , to assess whether presynaptic voltagegated calcium channels are involved in the response of minocycline. NiCl 2 (100 lM) alone decreased the frequency and amplitude of sIPSCs to 60 ± 3% (n = 9; P < 0.05) and 84 ± 4% (n = 9; P < 0.05) of the control (2.6 ± 0.3 Hz and 37.7 ± 4.6 pA), respectively. Pretreatment with NiCl 2 for 4 min diminished the enhancement of inhibitory synaptic transmission by minocycline (Fig. 5B) . The frequency and amplitude of sIPSCs were 97 ± 1% (n = 9, P > 0.05) and 101 ± 2% (n = 9, P > 0.05) of the control (1.6 ± 0.2 Hz and 31.9 ± 4.8 pA), respectively. Moreover, the HVA calcium channel blocker CdCl 2 had an effect similar to NiCl 2 (Fig. 5C ). CdCl 2 decreased the frequency and amplitude of sIPSCs to 25 ± 4% (n = 11; P < 0.05) and 64 ± 5% (n = 11; P < 0.05) of the control (2.7 ± 0.2 Hz and 34.3 ± 2.9 pA), respectively. The frequency and amplitude of sIPSCs pretreated with CdCl 2 in the presence of minocycline were 105 ± 3% (n = 11, P > 0.05) and 101 ± 2% (n = 11, P > 0.05) of the control (0.7 ± 0.2 Hz and 21.0 ± 1.1 pA), respectively. These findings demonstrate that presynaptic calcium channels inhibit the facilitation of minocycline on GABA/glycine release.
DISCUSSION
This study reveals a novel cellular mechanism by which minocycline decreases the excitability of SG neurons through a presynaptic mechanism that increases inhibitory neurotransmitter release.
Minocycline, a semisynthetic tetracycline, is well known for its functions, such as neuroprotection or antihypernociception, that have been identified in the last decade, and it typically acts by blocking microglial activation and reducing proinflammatory cytokine production (Yong et al., 2004) . However, some publications have demonstrated that minocycline may affect fast synaptic transmission; therefore, other potential mechanisms should not be ruled out. Moreover, the effect of minocycline may differ on different types of neurons. For example, minocycline (50 nM) had no effect on basal excitatory synaptic transmission in CA1 (Pascual et al., 2012) or SG neurons (Berta et al., 2014) ; however, 100 lM minocycline may inhibit dorsal root entry zone stimulation-elicited EPSCs in SG neurons (Cho et al., 2006) or may decrease sEPSC frequency and amplitude in hippocampal neurons (Gonzalez et al., 2007) . At a concentration of 200 lM, minocycline may decrease C-fiber evoked field potentials in the spinal dorsal horn, indicating an inhibition of excitatory synaptic transmission (Zhong et al., 2010) . In addition, minocycline at 500 lM abolished the mustard oil-induced glutamatergic-dependent central sensitization in medullary dorsal horn nociceptive neurons (Itoh et al., 2011) . The above observations suggest that minocycline may decrease neuronal excitability in a concentration-and cell-type-dependent manner by decreasing glutamatergic transmission. In addition to excitatory input, neurons also receive inhibitory synaptic transmission. If minocycline could modulate inhibitory synaptic transmission, then IPSC frequency or amplitude must be influenced by minocycline. In the present study, we focused on inhibitory transmission because disinhibition of SG neurons is an important mechanism of pathological pain (Todd, 2010) . Our study showed that minocycline increased sIPSC and mIPSC frequency without changing the amplitude. Generally, the increase in sIPSC or sEPSC frequency enhanced the probability of neurotransmitter release from the presynaptic terminal. Thus, the effect of minocycline on SG neurons is mainly of a presynaptic origin rather than a postsynaptic origin. The observation that minocycline had no effect on exogenous GABA-induced current further demonstrates this finding (Gonzalez et al., 2007) . Our previous study found that minocycline could inhibit hyperpolarization-activated cyclic nucleotide-gated (HCN) channels in SG neurons (Liu et al., 2015) . Both of these two effects of minocycline suggest it could be used as an analgesic.
Although microglial activation is usually found from 1 to 3 days after nerve injury (Inoue and Tsuda, 2009 ), we cannot absolutely exclude a glia-mediated effect of minocycline. It has been reported that the activity of astrocytes would be triggered by activation of microglia in pathological pain (Pascual et al., 2012) . Moreover, pretreatment of brain slices with fluorocitrate (100 lM for 30 min) increased sIPSC duration in ventrobasal nucleus neurons or decreased sIPSC duration in the thalamic reticular nucleus neurons (Christian and Huguenard, 2013) . Thus, we next investigated whether fluorocitrate has the same effect as minocycline in sIPSCs of SG neurons. Unexpectedly, neither the frequency nor the amplitude of sIPSCs was affected by fluorocitrate. We also investigated the response of minocycline to pretreatment with fluorocitrate. Again, we found that fluorocitrate does not alter the effect of minocycline. Therefore, it can be concluded that, at least in the current study, sIPSC enhancement by minocycline is not due to glial activation. Like minocycline, doxycycline is also effective at blocking pathological pain in animal models (Bastos et al., 2007) . This effect is potentially regulated by the same mechanism as the effect of minocycline. In our study, however, doxycycline could not mimic minocycline's facilitation of inhibitory transmission. Thus, it is improbable that the response of minocycline is produced by microglial activation or by its antibiotic effect.
It is well known that there are many inhibitory axon terminals, including monoamine-or GABA-containing descending fibers and inhibitory interneurons in SG (Todd, 2010) . GABA and glycine have been found to be coreleased in the spinal dorsal horn (Jonas et al., 1998) . Therefore, minocycline should exert the same effect on glycinergic and GABAergic sIPSCs. Accordingly, we observed that both strychnine-sensitive, glycine receptor-mediated sIPSCs and bicuculline-sensitive, GABA A receptor-mediated sIPSCs are enhanced by minocycline.
Neurotransmitter release from the presynaptic terminal is triggered by a Na + channel-dependent action potential, a subthreshold depolarizing current spread from the somatodendritic region, and presynaptic ligandgated channel activation. For example, an endogenous peptide antisecretory factor reduced the frequency of sIPSCs, but not mIPSCs, in CA1 pyramidal neurons (Strandberg et al., 2014) . Likewise, if an increase in sIPSC frequency is triggered by a Na + channeldependent action potential, then the Na + channel blocker TTX should block the effect of minocycline. In contrast, the increase in mIPSC frequency induced by minocycline was not blocked by bath application of TTX. It has been demonstrated that Na + channels, which account for action potential propagation expressed in lamina I/II of the spinal cord, are entirely TTX-sensitive (Hildebrand et al., 2011) . Therefore, our results together with the published literature suggest that a Na + channel-dependent action potential is not involved in the effect of minocycline on inhibitory transmission. It remains unclear whether a subthreshold depolarizing current spread from the somatodendritic region contributes to minocycline response. We next investigated whether glutamate receptormediated sEPSCs are involved in the increase in GABA and glycine release. Our data show that the effect of minocycline under the treatment with CNQX and APV was the same as with TTX. Therefore, it is possible that the enhancement of inhibitory neurotransmitter release is due to presynaptic ligand-gated channel activation. The spontaneous synaptic neurotransmitter release of dorsal horn neurons relies critically on presynaptic Frequency and amplitude were measured around 3 min after beginning of minocycline (100 lM) superfusion under various conditions. Values are mean ± SEM. * P < 0.05.
voltage-gated calcium channels (Bourinet et al., 2014) . In the present study, sIPSC frequency was largely inhibited in a Ca
2+
-free Krebs solution, indicating that voltagegated calcium channels possibly contribute to this effect. Based on the voltage dependence of activation, calcium channels in the spinal dorsal horn can be divided into two groups: HVA and LVA calcium channels (Bourinet et al., 2014) . Given that LVA calcium channels open at voltages near resting membrane potential, it is possible that these channels contribute to the response of minocycline. We first investigated the effect of the LVA calcium channel blocker NiCl 2 and found that it blocked minocycline's facilitation of sIPSC frequency. Meanwhile, the HVA calcium channel blocker CdCl 2 also blocked the -free Krebs solution (n = 11), NiCl 2 (n = 9) and CdCl 2 (n = 11), relative to the control. effect of minocycline. Thus, our results demonstrated that minocycline enhanced GABA and glycine release for the activation of presynaptic voltage-gated calcium channels.
The neuronal circuit of SG is composed of complex synaptic connections and plays an important role in pain signaling. Disinhibition, i.e., the reduction of GABAergic and/or glycinergic inhibitory transmission in the spinal dorsal horn, has been suggested to underlie the mechanisms of chronic pain (Todd, 2010) . In contrast, drugs, such as norepinephrine (Georgiev et al., 2006) and serotonin (Abe et al., 2009 ) that enhance inhibitory transmission and, therefore, lead to a reduction in neuronal excitability could be used as antinociceptive agents. Although the facilitatory effect of minocycline on inhibitory transmission in SG neurons is less pronounced compared with the effects of norepinephrine or serotonin, as mentioned above, minocycline has been shown to be an effective analgesic in a variety of animal pain models (GarridoMesa et al., 2013) . In addition, minocycline displays an enhanced antinociceptive effect when co-administered with non-steroidal anti-inflammatory drugs, including indomethacin or aspirin (Abu-Ghefreh and Masocha, 2010; Bhatt and Addepalli, 2010; Parvathy and Masocha, 2015) . Furthermore, minocycline raised the analgesic effect of dynorphin , nociceptin (Popiolek-Barczyk et al., 2014) , and tramadol (Mei et al., 2013) . We have recently shown that minocycline could decrease neuronal excitability by reducing the firing rates in response to depolarizing current injection in SG neurons (Liu et al., 2015) . In accordance with this report, we found that minocycline could enhance inhibitory presynaptic transmission due to an increased probability of release from nerve terminals, resulting in the inhibition of SG neurons.
CONCLUSIONS
Taken together, our results elucidate a novel cellular mechanism underlying minocycline-induced enhancement of inhibitory synaptic transmission in superficial spinal dorsal horn neurons. This action of minocycline may lead to the decreased excitability of SG neurons and may play a potential role in the modulation of neuropathic pain.
